,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['mbc', 'breast', 'destiny-breast04']
plenary abstract 3: dr. modi: destiny-breast04, t-dxd vs chemo in her2 low mbc. dropping the summary slide first, and commenting on how this affects 50% of patients with her2+ mbc. #asco22 
Gastrointestinal medical oncology, cancer of unknown primary, and value-based cancer care delivery. Tweets mine.